1. Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations in trial in high cardiovascular risk patients;Medicines and Healthcare products Regulatory Agency;Drug Safety Update,2016
2. Invokana 100 mg film-coated tablets. Summary of product characteristics, EU. Janssen-Cilag International NV, April 2016.
3. Vokanamet 50mg/850mg film-coated tablets. Summary of product characteristics, EU. Janssen-Cilag International NV, April 2016.
4. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
5. Empagliflozin, diabetes and outcomes;DTB,2016